Open AccessLong‐term survival in women with borderline ovarian tumors: a population‐based survey of borderline ovarian tumors in Sweden 1960–2007
Author(s) -
Kalapotharakos Grigorios,
Högberg Thomas,
Bergfeldt Kjell,
Borgfeldt Christer
Publication year - 2016
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1111/aogs.12846
Subject(s) - medicine , relative survival , serous fluid , incidence (geometry) , relative risk , population , cancer registry , ovarian cancer , survival rate , ovary , gynecology , epidemiology , oncology , cancer , confidence interval , physics , environmental health , optics
We conducted an evaluation of incidence and survival of women with borderline ovarian tumors in Sweden. Material and methods All women diagnosed with borderline ovarian tumor in the Swedish Cancer Register 1960–2007 ( n = 6252) combined with follow up in the Swedish Death Registry to 1 July 2009 were included. Estimation of age‐standardized relative survival rate according to time periods for diagnosis. Results The incidence of borderline ovarian tumors increased during the study period, with a steep increase during the 1980s. The age standardized 5‐year relative survival including all borderline tumors diagnosed 2000–07 was 97% (95% CI 92–99%). In women aged ≤64 years, the 10‐year relative survival related to age at diagnosis of borderline tumors ranged from 95 to 98% and was 89% in women aged 65–74 years. In a multivariable analysis including age and decade of diagnosis relative survival for every decade increased. The 10‐year relative survival in women with mucinous and serous borderline tumors did not differ significantly ( p = 0.121). Conclusions Results of the present study are reassuring about long‐term survival in women with borderline ovarian tumors. The age‐standardized relative survival rate increased across time periods for diagnosis. There was no difference in long‐term survival between mucinous and serous borderline ovarian tumors.